Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 7.4% – Should You Buy?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price was up 7.4% on Monday . The stock traded as high as $20.31 and last traded at $20.95. Approximately 42,144 shares were traded during trading, a decline of 84% from the average daily volume of 259,438 shares. The stock had previously closed at $19.50.

Analyst Upgrades and Downgrades

A number of brokerages have commented on DNTH. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Wedbush restated an “outperform” rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, Guggenheim reiterated a “buy” rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Dianthus Therapeutics has a consensus rating of “Buy” and a consensus price target of $54.33.

Dianthus Therapeutics Stock Performance

The company has a market cap of $702.60 million, a P/E ratio of -8.75 and a beta of 1.62. The stock’s fifty day moving average price is $20.14 and its two-hundred day moving average price is $23.00.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $1.33 million during the quarter, compared to analysts’ expectations of $1.40 million. On average, equities research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. MetLife Investment Management LLC grew its stake in shares of Dianthus Therapeutics by 3.1% during the fourth quarter. MetLife Investment Management LLC now owns 14,372 shares of the company’s stock worth $313,000 after buying an additional 433 shares during the last quarter. Invesco Ltd. grew its position in Dianthus Therapeutics by 7.4% during the 4th quarter. Invesco Ltd. now owns 11,521 shares of the company’s stock worth $251,000 after acquiring an additional 790 shares during the last quarter. SG Americas Securities LLC grew its position in Dianthus Therapeutics by 9.2% during the 4th quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock worth $210,000 after acquiring an additional 814 shares during the last quarter. Barclays PLC increased its holdings in Dianthus Therapeutics by 2.6% in the 4th quarter. Barclays PLC now owns 42,766 shares of the company’s stock worth $933,000 after purchasing an additional 1,082 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Dianthus Therapeutics by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company’s stock valued at $3,641,000 after purchasing an additional 1,092 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.